The doses in the countries they're at now aren't likely to go to a different country, and are more likely to expire before they could be shipped elsewhere, so p

The doses in the countries they're at now aren't likely to go to a different country, and are more likely to expire before they could be shipped elsewhere, so people in those countries may as well get them. For other places, the problem is manufacturing and distribution, and lifting patent restrictions would help too.